In a compelling Genomic Press Interview published today in Brain Medicine, Sophia Shi, PhD, unveils her pioneering research that fundamentally changes our understanding of brain aging and opens revolutionary therapeutic pathways for Alzheimer's disease and related neurodegenerative conditions.

Uncovering the Brain's Hidden Shield

Dr. Shi's groundbreaking work focuses on the glycocalyx, a complex "forest" of sugar molecules coating blood-brain barrier endothelial cells. Her research, recently published in Nature, demonstrates that this protective layer deteriorates dramatically with age, leading to blood-brain barrier dysfunction and neuroinflammation, key drivers of cognitive decline and neurodegenerative diseases.

"The glycocalyx acts like a protective shield for the brain's blood vessels," Dr. Shi explains. "When we restored these critical sugar molecules in aged mice, we saw remarkable improvements in both barrier integrity and cognitive function." This discovery represents the first time scientists have successfully reversed age-related blood-brain barrier dysfunction through glycocalyx restoration.

From Puzzles to Proteins: A Scientific Journey

Dr. Shi's path to this breakthrough began with childhood fascinations with puzzles and pattern recognition, skills that would later prove invaluable in decoding the complex language of glycosylation. Working under the mentorship of Nobel laureate Carolyn Bertozzi and renowned neurobiologist Tony Wyss-Coray at Stanford, she bridged two distinct fields, glycobiology and neuroscience, to tackle questions others had overlooked.

Her interdisciplinary approach faced significant challenges. How do you study molecules so structurally complex that they've resisted traditional analysis methods? What techniques can capture the dynamic nature of glycosylation in living brain tissue? Dr. Shi's innovative solutions to these problems exemplify the power of cross-disciplinary thinking in modern biomedical research.

Recognition and Research Excellence

The impact of Dr. Shi's work extends far beyond the laboratory. Her research garnered the prestigious David S. Miller Young Scientist Award at the Cerebral Vascular Biology Conference, recognizing her as one of the field's most promising young investigators. Perhaps more remarkably, she is launching her independent laboratory at Harvard's prestigious Rowland Institute directly from doctoral training -- a rare achievement that speaks to the transformative potential of her discoveries.

"Post-translational modifications like glycosylation have been understudied for too long," Dr. Shi notes. "These modifications can completely transform protein function, yet we're only beginning to understand their role in brain health and disease." Her work positions glycoscience at the forefront of neurodegeneration research, challenging long-held assumptions about therapeutic targets.

Therapeutic Implications and Future Directions

The therapeutic implications of Dr. Shi's findings are profound. By identifying specific mucin-type O-glycans as critical for blood-brain barrier integrity, her research provides concrete molecular targets for drug development. This precision approach could lead to treatments that address the root causes of neurodegeneration rather than merely managing symptoms.

Intriguing questions emerge from this work: Can glycocalyx restoration prevent or slow Alzheimer's disease progression in humans? How early in the aging process do these protective molecules begin to deteriorate? What environmental or genetic factors influence glycocalyx health throughout the lifespan? These questions will drive the next phase of Dr. Shi's research program at Harvard.

Building an Inclusive Scientific Future

Beyond her scientific contributions, Dr. Shi is committed to fostering diversity in science. "It's easy to feel isolated or like you don't belong in science, especially without early exposure or role models," she reflects. Her dedication to mentoring and creating inclusive research environments promises to amplify her impact by inspiring the next generation of interdisciplinary scientists.

The interview reveals how personal experiences shape scientific pursuits. Dr. Shi's appreciation for hiking and trail running mirrors her approach to research: seeking new perspectives from challenging vantage points. This blend of rigorous science with human experience characterizes the new generation of biomedical researchers.Implications for Brain Medicine

Dr. Shi's discoveries raise fundamental questions about how we approach brain aging and disease. If glycocalyx deterioration is a common pathway in multiple neurodegenerative conditions, could targeting these molecules provide a unified therapeutic strategy? How might lifestyle factors influence glycocalyx health? These considerations could reshape preventive medicine approaches for brain health.

The transition from viewing the blood-brain barrier as a simple wall to understanding it as a dynamic, sugar-coated interface represents a paradigm shift in neuroscience. This new perspective demands innovative research approaches and may explain why previous therapeutic strategies targeting the barrier have shown limited success.

Dr. Sophia Shi's Genomic Press interview is part of a larger series called Innovators & Ideas that highlights the people behind today's most influential scientific breakthroughs. Each interview in the series offers a blend of cutting-edge research and personal reflections, providing readers with a comprehensive view of the scientists shaping the future. By combining a focus on professional achievements with personal insights, this interview style invites a richer narrative that both engages and educates readers. This format provides an ideal starting point for profiles that explore the scientist's impact on the field, while also touching on broader human themes.

Read more …Sugar shield restored: The breakthrough reversing brain aging and memory loss

Your breath is one of a kind. A study published June 12 in the Cell Press journal Current Biology demonstrated that scientists can identify individuals based solely on their breathing patterns with 96.8% accuracy. These nasal respiratory "fingerprints" also offer insights into physical and mental health.

The research stemmed from the lab's interest in olfaction, or the sense of smell. In mammals, the brain processes odor information during inhalation. This link between the brain and breathing led researchers to wonder: since every brain is unique, wouldn't each person's breathing pattern reflect that?

To test the idea, the team developed a lightweight wearable device that tracks nasal airflow continuously for 24 hours using soft tubes placed under the nostrils. Most breathing tests last just one to 20 minutes, focusing on evaluating lung function or diagnosing disease. But those brief snapshots aren't enough to capture subtle patterns.

"You would think that breathing has been measured and analyzed in every way," says author Noam Sobel of the Weizmann Institute of Science, Israel. "Yet we stumbled upon a completely new way to look at respiration. We consider this as a brain readout."

Sobel's team fitted 100 healthy young adults with the device and asked them to go about their daily lives. Using the collected data, the team identified individuals using only their breathing patterns with high accuracy. This high-level accuracy remained consistent across multiple retests conducted over a two-year period, rivaling the precision of some voice recognition technologies.

"I thought it would be really hard to identify someone because everyone is doing different things, like running, studying, or resting," says author Timna Soroka of the Weizmann Institute of Science. "But it turns out their breathing patterns were remarkably distinct."

Moreover, the study found that these respiratory fingerprints correlated with a person's body mass index, sleep-wake cycle, levels of depression and anxiety, and even behavioral traits. For example, participants who scored relatively higher on anxiety questionnaires had shorter inhales and more variability in the pauses between breaths during sleep. Soroka noted that none of the participants met clinical diagnostic criteria for mental or behavioral conditions. The results suggest that long-term nasal airflow monitoring may serve as a window into physical and emotional well-being.

"We intuitively assume that how depressed or anxious you are changes the way you breathe," says Sobel. "But it might be the other way around. Perhaps the way you breathe makes you anxious or depressed. If that's true, we might be able to change the way you breathe to change those conditions."

The current device still faces real-world challenges. A tube that runs under the nose is often associated with illness and may deter adoption. The device also doesn't account for mouth breathing and can slip out of place when sleeping. The team aims to design a more discreet and comfortable version for everyday use.

Soroka and Sobel are already investigating whether people can mimic healthy breathing patterns to improve their mental and emotional states. "We definitely want to go beyond diagnostics to treatment, and we are cautiously optimistic," says Sobel.

Read more …Invisible ID: How a single breath could reveal your health—and your identity

A new study to be presented at the SLEEP 2025 annual meeting found that teens who get moderate -- but not excessive -- catch-up sleep on weekends have fewer symptoms of anxiety.

Results show that teens who got up to two more hours of sleep on weekends than on weekdays exhibited fewer anxiety symptoms compared with those who did not sleep longer on weekends. However, longer durations of catch-up sleep on weekends were associated with slightly more internalizing symptoms.

"The results show that both sleeping less on weekends than weekdays and sleeping substantially more on weekends were associated with higher anxiety symptoms," said lead author Sojeong Kim, a doctoral candidate in the department of clinical psychology and psychology graduate advisor at the University of Oregon in Eugene. "In contrast, moderate catch-up sleep -- defined as less than two hours -- was associated with lower anxiety symptoms, suggesting that some weekend recovery sleep may be beneficial."

The American Academy of Sleep Medicine recommends that teenagers 13 to 18 years of age should sleep 8 to 10 hours on a regular basis to promote optimal health. However, CDC data show that only 23% of high school students get sufficient sleep on an average school night.

"Many teens try to make up for lost sleep by sleeping in on weekends," Kim said.

Consistently getting sufficient sleep is associated with better health outcomes including improved attention, behavior, learning, memory, emotional regulation, quality of life, and mental and physical health. In contrast, insufficient sleep in teenagers is associated with increased risks of problems such as depression and suicidal thoughts.

The study involved 1,877 adolescents with a mean age of 13.5 years. Sleep duration was estimated using Fitbit devices, while internalizing symptoms were assessed using the Child Behavior Checklist survey. Weekend catch-up sleep was calculated as the difference between weekend and weekday sleep duration.

Kim noted that it is important to identify the right amount of catch-up sleep that is beneficial to teens who restrict their sleep during the week.

"Too little or too much sleep variability from weekday to weekend may contribute to the symptoms someone is trying to combat, like physical or mental fatigue and feelings of anxiety," she said.

The research abstract was published recently in an online supplement of the journal Sleep and will be presented Wednesday, June 11, during SLEEP 2025 in Seattle. SLEEP is the annual meeting of the Associated Professional Sleep Societies, a joint venture of the American Academy of Sleep Medicine and the Sleep Research Society.

Abstract Title: The Sweet Spot of Weekend Catch-Up Sleep: A Protective Factor Against Depressive Symptoms?

Abstract ID: 0263

Read more …Sleep-in science: How 2 extra weekend hours can calm teen anxiety

Genetic material shed by tumors can be detected in the bloodstream three years prior to cancer diagnosis, according to a study led by investigators at the Ludwig Center at Johns Hopkins, Johns Hopkins Kimmel Cancer Center, the Johns Hopkins University School of Medicine and the Johns Hopkins Bloomberg School of Public Health.

The study, partly funded by the National Institutes of Health, was published May 22 in Cancer Discovery.

Investigators were surprised they could detect cancer-derived mutations in the blood so much earlier, says lead study author Yuxuan Wang, M.D., Ph.D., an assistant professor of oncology at the Johns Hopkins University School of Medicine. "Three years earlier provides time for intervention. The tumors are likely to be much less advanced and more likely to be curable."

To determine how early cancers could be detected prior to clinical signs or symptoms, Wang and colleagues assessed plasma samples that were collected for the Atherosclerosis Risk in Communities (ARIC) study, a large National Institutes of Health-funded study to investigate risk factors for heart attack, stroke, heart failure and other cardiovascular diseases. They used highly accurate and sensitive sequencing techniques to analyze blood samples from 26 participants in the ARIC study who were diagnosed with cancer within six months after sample collection, and 26 from similar participants who were not diagnosed with cancer.

At the time of blood sample collection, eight of these 52 participants scored positively on a multicancer early detection (MCED) laboratory test. All eight were diagnosed within four months following blood collection. For six of the eight individuals, investigators also were able to assess additional blood samples collected 3.1-3.5 years prior to diagnosis, and in four of these cases, tumor-derived mutations could also be identified in samples taken at the earlier timepoint.

"This study shows the promise of MCED tests in detecting cancers very early, and sets the benchmark sensitivities required for their success," says Bert Vogelstein, M.D., Clayton Professor of Oncology, co-director of the Ludwig Center at Johns Hopkins and a senior author on the study.

"Detecting cancers years before their clinical diagnosis could help provide management with a more favorable outcome," adds Nickolas Papadopoulos, Ph.D., professor of oncology, Ludwig Center investigator and senior author of the study. "Of course, we need to determine the appropriate clinical follow-up after a positive test for such cancers."

The study was supported in part by National Institutes of Health grant #s R21NS113016, RA37CA230400, U01CA230691, P30 CA 06973, DRP 80057309, and U01 CA164975. Additional funding was provided by the Virginia and D.K. Ludwig Fund for Cancer Research, the Commonwealth Fund, the Thomas M Hohman Memorial Cancer Research Fund, The Sol Goldman Sequencing Facility at Johns Hopkins, The Conrad R. Hilton Foundation, the Benjamin Baker Endowment, Swim Across America, Burroughs Wellcome Career Award for Medical Scientists, Conquer Cancer -- Fred J. Ansfield, MD, Endowed Young Investigator Award, and The V Foundation for Cancer Research. The Atherosclerosis Risk in Communities study has been funded in whole or in part with federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under contract numbers 75N92022D00001, 75N92022D00002, 75N92022D00003, 75N92022D00004, and 75N92022D00005.

Read more …Johns Hopkins blood test detects tumor dna three years early

More Articles …